Literature DB >> 25449984

Functional outcome after resuscitative endovascular balloon occlusion of the aorta of the proximal and distal thoracic aorta in a swine model of controlled hemorrhage.

Kira N Long1, Robert Houston2, J Devin B Watson2, Jonathan J Morrison3, Todd E Rasmussen4, Brandon W Propper2, Zachary M Arthurs2.   

Abstract

BACKGROUND: Noncompressible torso hemorrhage remains an ongoing problem for both military and civilian trauma. Resuscitative endovascular balloon occlusion of the aorta (REBOA) has been characterized as a potentially life-saving maneuver. The objective of this study was to determine the functional outcomes, paraplegia rates, and survival of 60-min balloon occlusion in the proximal and distal thoracic aorta in a porcine model of controlled hemorrhage.
METHODS: Swine (Sus scrofa, 70-110 kg) were subjected to class IV hemorrhagic shock and underwent 60 min of REBOA. Devices were introduced from the left carotid artery and positioned in the thoracic aorta in either the proximal location (pREBOA [n = 8]; just past takeoff of left subclavian artery) or distal location (dREBOA [n = 8]; just above diaphragm). After REBOA, animals were resuscitated with whole blood, crystalloid, and vasopressors before a 4-day postoperative period. End points included evidence of spinal cord ischemia (clinical examination, Tarlov gait score, bowel and bladder dysfunction, and histopathology), gross ischemia-reperfusion injury (clinical examination and histopathology), and mortality.
RESULTS: The overall mortality was similar between pREBOA and dREBOA groups at 37.5% (n = 3). Spinal cord-related mortality was 12.5% for both pREBOA and dREBOA groups. Spinal cord symptoms without death were present in 12.5% of pREBOA and dREBOA groups. Average gait scores improved throughout the postoperative period.
CONCLUSIONS: REBOA placement in the proximal or distal thoracic aorta does not alter mortality or paraplegia rates as compared with controlled hemorrhage alone. Functional recovery improves in the presence or the absence of REBOA, although at a slower rate after REBOA as compared with negative controls. Additional research is required to determine the ideal placement of REBOA in an uncontrolled hemorrhage model to achieve use compatible with survival outcomes and quality of life.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25449984     DOI: 10.1016/j.avsg.2014.10.004

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  5 in total

Review 1.  Emerging Endovascular Therapies for Non-Compressible Torso Hemorrhage.

Authors:  Rachel M Russo; Lucas P Neff; Michael Austin Johnson; Timothy K Williams
Journal:  Shock       Date:  2016-09       Impact factor: 3.454

Review 2.  Resuscitative endovascular balloon occlusion of the aorta in combat casualties: The past, present, and future.

Authors:  Sarah C Stokes; Christina M Theodorou; Scott A Zakaluzny; Joseph J DuBose; Rachel M Russo
Journal:  J Trauma Acute Care Surg       Date:  2021-08-01       Impact factor: 3.697

3.  Directly Cooling Gut Prevents Mortality in the Rat Model of Reboa Management of Lethal Hemorrhage.

Authors:  Chunli Liu; Dong Yuan; Robert Crawford; Rajabrata Sarkar; Bingren Hu
Journal:  Shock       Date:  2021-11-01       Impact factor: 3.533

Review 4.  Damage control approach to refractory neurogenic shock: a new proposal to a well-established algorithm.

Authors:  Michael W Parra; Carlos A Ordoñez; David Mejia; Yaset Caicedo; Javier Mauricio Lobato; Oscar Javier Castro; Jose Alfonso Uribe; Fernando Velásquez
Journal:  Colomb Med (Cali)       Date:  2021-06-30

Review 5.  Prehospital control of life-threatening truncal and junctional haemorrhage is the ultimate challenge in optimizing trauma care; a review of treatment options and their applicability in the civilian trauma setting.

Authors:  S E van Oostendorp; E C T H Tan; L M G Geeraedts
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2016-09-13       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.